Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a Massachusetts based leader in non-invasive hemodynamic monitoring, announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock. Initial results of this study were previously presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) Congress in Brussels, and the full study is now published online in the Journal of Critical Care.

The results, authored by Drs. Heath Latham and Steven Q. Simpson from the University of Kansas Health System, demonstrate strong clinical value for fluid resuscitation strategies using Stroke Volume and dynamic assessments, and guided by Cheetah Medical technology:

- ICU Length of Stay: reduced by 2.89 days
- Risk of Mechanical Ventilation: reduced by 51%
- Initiation of Acute Dialysis Therapy: reduced by 13.25%
- Pressor Use: reduced by 32.78 hours
- Fluid Balance: reduced by 3.59L

Sepsis is the most expensive inpatient cost to hospitals in the United States, costing an average of $25,000 – $50,0001 per episode. The positive clinical outcomes from this study, in turn, can enhance patient safety and result in a significant reduction of these costs.

Major societies, including the Surviving Sepsis Campaign and National Quality Forum, have recently updated their sepsis management guidelines to recommend dynamic assessment of fluid responsiveness. Research shows that serious complications can result from giving a patient too little or too much IV fluids, which can lead to increased length of stay, increased mortality and increased complications.

“This study builds on the broad outcome data in the surgical literature showing the value of using dynamic assessments to guide fluid management. It is exciting to see the role that Cheetah can play in these strategies to improve care in sepsis patients.” said Dr. Doug Hansell, Chief physician Executive at Cheetah Medical.

Dr. Heath Latham from the University of Kansas Health System, comments, “We embarked on this study with the hypothesis that actively managing patients’ fluids was associated with improved clinical outcomes. The study demonstrated positive patient outcomes from actively monitoring resuscitation by optimizing stroke volume, that can be translated to significant cost savings to the hospitals caring for these very critical patients. University of Kansas Health System realized an associated savings of about $14 million for 1,000 sepsis patients that were monitored by Cheetah technology.”

Details about the factors making up these financial savings can be found at

About Cheetah Medical
Cheetah Medical is the pioneer and leading global provider of 100% noninvasive hemodynamic monitoring technologies which are designed for use in critical care, operating room, general care floor, and emergency department settings. The CHEETAH NICOM™ and STARLING™ SV technologies use a proprietary algorithm to provide accurate and precise data, enabling clinicians to quickly see a patient’s full hemodynamic profile. Medical professionals use this information to assess patients’ unique volume requirements, guide volume management decisions and maintain adequate organ perfusion. Cheetah Medical technologies are designed to enable more confident, informed therapy decisions that support clinical goals of improving patient outcomes and driving economic efficiencies.

1 Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther 2012; 10(6) 701-706.

Cheetah Medical, Inc.

Cheetah Medical, Inc.
Non-invasive haemodynamic monitoring


DownloadPress Release

Latest News

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.

VitalConnect Announces Closure of $33m Series C Financing

VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.

MVM invests €15.2m in Valneva SE

Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera